Supporting Information

Structure-Activity Relationship of Truncated 2,8-Disubstituted-adenosine Derivatives as Dual A_{2A}/A₃ Adenosine Receptor Antagonists and their Cancer Immunotherapeutic Activity

Gibae Kim,¹ Xiyan Hou,^{1,2} Woong Sub Byun,^{1,3} Gyudong Kim,^{1,4} Dnyandev B. Jarhad,¹ Grim Lee,¹ Young Eum Hyun,¹ Jinha Yu,^{1,5} Chang Soo Lee,¹ Shuhao Qu,¹ Eugene Warnick,⁶ Zhan-Guo Gao,⁶ Ji Yong Kim,⁷ Seunghee Ji,⁸ Hyunwoo Shin,⁸ Jong-Ryoul Choi,⁸ Kenneth A. Jacobson,⁶ Hyuk Woo Lee,⁷ Sang Kook Lee,¹ Lak Shin Jeong^{1,7,*}

¹Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea, ²College of Life Science, Dalian Minzu University, Dalian 116600, People's Republic of China, ³Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States, ⁴College of Pharmacy & Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea, ⁵College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, South Korea, ⁶Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland 20892, USA, and ⁷Future Medicine Co., Ltd, Seoul 06665, Republic of Korea, ⁸HK inno.N Corp., Seoul 04551, Republic of Korea.

*Corresponding authors: lakjeong@snu.ac.k

Table of Contents

Additional <i>in vitro</i> data and procedures	S3
Single-Crystal X-ray crystallography data of compounds 11b, 22a and 22b	S5
Reference	S11
HPLC data of the representative compounds	S12
¹ H and ¹³ C NMR of the compounds	

Additional in vitro data and procedures

Table S1. The cAMP functional assay of A2AAR with 100 nM of full agonist CGS21680

Compound	% inhibition, A _{2A} AR cAMP functional assay
5a	53.47%
5d	63.82%
5g	12.31%

Table S2. The result of *in vitro* CYP inhibition assay

Commonia		%	inhibition at 10 μ	М	
Compound	CYP1A2	CYP2C9	CYP2C19	CYP2D6	CYP3A4
5d	14%	4%	6%	3%	0%

Table S3. The result of *in vitro* hERG inhibition assay

Compound —		% inhibition	
	$1 \mu M$	3 µM	10 µM
5d	13%	18%	31%

Cyclic AMP Accumulation Assay with CGS-21680. Human adenosine receptor functional experiments were carried out in A_{2A}AR-HEK293 cell line for hA_{2A}AR. The cells are seeded on the 96 well culture plate (NUNC 136101) with stimulation buffer (1X HBSS, Gibco 14025092; 7.5% BSA stabilizer; 250 mM IBMX, Sigma I5879; 1 M HEPES). 10 μ M of test compound and 100 nM of CGS-21680 (**26**) are added, then the cells are centrifuged at 500 rpm for 3 min, followed by incubated at 30 °C for 30 min. After incubation, the amount of cAMP is determined using LANCE Ultra cAMP detection kit (Perkin Elmer TRF0262).

In vitro CYP inhibition assay. Human liver microsomes (0.25 mg/mL), 0.1 M phosphate buffer (pH 7.4), a cocktail of five coenzyme substrates (Phenacetin 50 μ M, Diclofenac 10 μ M, S-mephenytoin 100 μ M, Dextromethorphan 5 μ M, Midazolam 2.5 μ M), and test compound (10 μ M

concentration) was pre-incubated for 5 min at 37 °C. NADPH generation system solution was added and incubated for 15 min at 37 °C. In order to terminate the reaction, acetonitrile solution containing an internal standard (Terfenadine) was added and centrifuged for 5 min (14,000× g rpm, 4 °C). The supernatant was injected into the LC-MS/MS system to analyze the metabolites of the substrates simultaneously. Metabolites of each substrate produced during the reaction were analyzed using the Shimadzu Nexera XR system and TSQ vantage (Thermo). Kinetex C18 column (2.1 × 100 mm, 2.6 μ m particle size; Phenomenex, USA) was used for HPLC. The mobile phase used contained 0.1% formic acid in distilled water (A) and 0.1% formic acid containing acetonitrile (B). The generated metabolites were quantified using MRM (Multiple Reaction Monitoring) and Xcalibur (version 1.6.1) was used for data analysis.^{1,2}

In vitro hERG assay. CHO cells stably expressing hERG potassium channels from Sophion Biosciences were used for this test. The cells were cultured in a humidified and air-controlled $(5\% \text{ CO}_2)$ incubator at 37 °C. The CHO cells which were at least two days after plating and more than 75% confluent would be used for experiments. Before testing, cells were harvested using TrypLE and resuspended in the physiological solution at the room temperature. The physiological solution and external solution were prepared at least one month. The intracellular solution was prepared in batches aliquoted, and stored at 4 °C until used. Test compounds were dissolved in 100% DMSO at 10 mM to obtain stock solutions for different test concentrations. Then the stock solutions were further diluted into external solution to achieve final concentrations for testing. Visual check for precipitation was conducted before testing. Final DMSO concentration in extracellular solution was not more than 0.30% for the test compounds. hERG SyncroPatch(384PE) assay was conducted at room temperature. The Setup, Prime Chip, Catch and Seal Cells, Amplifier Settings, Voltage and Application Protocols were established with Biomek Software (Nanion). One addition of 40 μ L of the vehicle was applied, followed by 300s for a baseline period. Then the doses of the compounds were added with 40 μ L. The exposure of test compound at each concentration was no less than 300s. The recording for the whole process had to pass the quality control or the well was abandoned and the compound was retested, all automatically set by PatchControl. Three concentrations (1.00 μ M, 3.00 μ M, and 10.00 μ M) were tested for each compound. Minimum 2 replicates per concentration were obtained.

Single-Crystal X-ray crystallography data of compounds 11b, 22a and 22b.

Compound **11b**, **22a** or **22b** (~10 mg) was dissolved in ethyl acetate and dichloromethane (1.0 mL, 1:4) in a glass vial. After staying at room temperature, the single crystals of **11b**, **22a** or **22b** were obtained. X-ray diffraction data of **11b** (CCDC No: 2164196), **22a** (CCDC No: 2164194), and **22b 22a** (CCDC No: 2258518) were obtained on a SuperNova, Dual, Cu at zero, AtlasS2 diffractometer. Using Olex2³, the structure was solved with the ShelXT⁴ structure solution program using Intrinsic Phasing and refined with the ShelXL⁴ refinement package using Least Squares minimization.





Figure S1. ORTEP diagram of compound 11b showing thermal ellipsoid at 50% probability.

/	
Empirical formula	$C_{19}H_{19}ClN_4O_3S$
Formula weight	418.89
Temperature/K	293(1)
Crystal system	monoclinic
Space group	C2
a/Å	25.4206(7)
b/Å	7.3860(2)
c/Å	10.6375(3)
α/°	90
β/°	96.378(2)
γ/°	90
Volume/Å ³	1984.90(10)
Z	4
$ ho_{calc}g/cm^3$	1.402
µ/mm ⁻¹	2.929
F(000)	872.0
Crystal size/mm ³	$0.563 \times 0.19 \times 0.087$
Radiation	$CuKa (\lambda = 1.54184)$
2Θ range for data collection/°	6.998 to 147.472
Index ranges	$-31 \le h \le 26, -8 \le k \le 8, -13 \le l \le 12$
Reflections collected	3649
Independent reflections	2927 [$R_{int} = 0.0113, R_{sigma} = 0.0187$]
Data/restraints/parameters	2927/1/256
Goodness-of-fit on F ²	1.036

Table S4. Crystal	data and structure	e refinement for	11b
-------------------	--------------------	------------------	-----

Final R indexes $[I \ge 2\sigma(I)]$	$R_1 = 0.0469, wR_2 = 0.1323$
Final R indexes [all data]	$R_1 = 0.0483$, $wR_2 = 0.1343$
Largest diff. peak/hole / e Å ⁻³	0.36/-0.19

Single-Crystal X-ray crystallography of compound **22***a*



Figure S2. ORTEP diagram of compound 22a showing thermal ellipsoid at 50% probability.

Empirical formula	$C_{19}H_{19}ClN_4O_3S$
Formula weight	418.89
Temperature/K	293(2)
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	7.1613(18)
b/Å	10.7229(15)
c/Å	25.009(4)
a/°	90
β/°	90
γ/°	90
Volume/Å ³	1920.5(6)
Z	4
$ ho_{calc}g/cm^3$	1.449
μ/mm^{-1}	0.337
F(000)	872.0
Crystal size/mm ³	$0.262 \times 0.114 \times 0.075$
Radiation	MoKa ($\lambda = 0.71073$)
2Θ range for data collection/°	5.004 to 58.788
Index ranges	$-8 \le h \le 8, -13 \le k \le 14, -25 \le l \le 34$
Reflections collected	11286
Independent reflections	4489 [$R_{int} = 0.0733$, $R_{sigma} = 0.1095$]

Table S5. Crystal data and structure refinement for 22a

Data/restraints/parameters	4489/0/256
Goodness-of-fit on F ²	1.073
Final R indexes $[I \ge 2\sigma(I)]$	$R_1 = 0.0743$, $wR_2 = 0.1247$
Final R indexes [all data]	$R_1 = 0.1233$, $wR_2 = 0.1459$
Largest diff. peak/hole / e Å ⁻³	0.42/-0.31

Single-Crystal X-ray crystallography of compound **22b**



Figure S3. ORTEP diagram of compound 22b showing thermal ellipsoid at 50% probability.

Empirical formula	$C_{19}H_{19}ClN_4O_2S_2$
Formula weight	434.97
Temperature/K	111.0(8)
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	7.0735(7)
b/Å	24.677(4)
c/Å	12.1455(13)
a/°	90
β/°	90
γ/°	90
Volume/Å ³	2120.0(4)
Z	4
$ ho_{calc}g/cm^3$	1.3627
μ/mm^{-1}	0.399
F(000)	905.9
Crystal size/mm ³	0.466 × 0.394 × 0.229
Radiation	Mo Ka (λ = 0.71073)
2Θ range for data collection/°	4.7 to 59.38
Index ranges	$-8 \le h \le 9, -34 \le k \le 29, -15 \le l \le 16$

Table S6. Crystal data and structure refinement for 22b

Reflections collected	23486
Independent reflections	$5357 [R_{int} = 0.0955, R_{sigma} = 0.0926]$
Data/restraints/parameters	5357/12/255
Goodness-of-fit on F ²	1.038
Final R indexes $[I \ge 2\sigma(I)]$	$R_1 = 0.0902$, $wR_2 = 0.2143$
Final R indexes [all data]	$R_1 = 0.1161, wR_2 = 0.2353$
Largest diff. peak/hole / e Å ⁻³	1.00/-0.90

Reference

(1) Kim, M.-J.; Kim, H.; Cha, I.-J.; Park, J.-S.; Shon, J.-H.; Liu, K.-H.; Shin, J.-G. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes *in vitro* using liquid chromatography/tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* **2005**, 19, 2651–2658.

(2) Kerns, E.H.; Di, L. (Eds.) *Chapter 32—CYP Inhibition Methods. Drug-like Properties: Concepts, Structure Design and Methods*, Academic Press: San Diego, CA, USA, 2008, pp. 360–3

(3) Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J; Howard, J. A. K.; Puschmann, H. J. Appl. Cryst. **2009**, *42*, 339-341..

(4) Sheldrick, G. M. Acta Cryst. 2015, A71, 3-8.

(5) Sheldrick, G. M. Acta Cryst. 2015, C71, 3-8.

HPLC data of the representative compounds

HPLC data of the compound **5d**

Sample Name: LJ4517 _____ Acq. Operator : SYSTEM Seq. Line : 4 Acq. Instrument : 1290 Infinity Location : P1-A-01 Injection Date : 3/14/2022 1:05:50 PM Inj: 1 Inj Volume : 10.000 µl Method : D:\Data\9171\9171_220314_KGB 2022-03-14 11-31-57\210809_KGB.M (Sequence Method) : 3/14/2022 11:31:57 AM by SYSTEM Last changed D1 A, Sig=320,4 Ref=off (D:/Data/9171/9171_220314_KGB 2022-03-14 11-31-57/L)4517.D - D:/DATA/9171/9171_220314_KGB 20 mAU 700 600 -500 -400 -300 -200 100 13.772 15311 훏 0 15 _____ Area Percent Report _____ Sorted By Signal : : 1.0000 Multiplier 1.0000 Dilution Do not use Multiplier & Dilution Factor with ISTDs Signal 1: DAD1 A, Sig=320,4 Ref=off Signal has been modified after loading from rawdata file! Peak RetTime Type Width Area Height Area # [min] [mAU*s] [mAU] % 1 2.748 BB 0.0527 10.08669 3.04008 0.2170 2 2.937 BB 0.1353 15.64708 1.53052 0.3366 3 13.772 BB 0.0918 22.83916 3.81585 0.4913 4 14.661 BB 0.0903 4589.68164 761.54034 98.7254 5 15.311 BB 0.0935 10.68061 1.74166 0.2297 Totals : 4648.93519 771.66846

Data File D:\Data\9171\9171_220314_KGB 2022-03-14 11-31-57\L34517.D

HPLC data of the compound **5***g*

Data File D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\KGB-II-76(1).D Sample Name: KGB-II-76(1)



HPLC data of the compound **5h**

Data File D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\KGB-II-74.D Sample Name: KGB-II-74

Acq. Operator : SYSTEM Seq. Line : 7 Acq. Instrument : 1290 Infinity Location : P1-A-01 Injection Date : 3/8/2019 5:35:04 PM Inj: 1 Inj Volume : 10.000 µl Sequence File : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\9171-190308_kim.S : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\190308_kim.M (Sequence Method Method) Last changed : 3/8/2019 3:14:53 PM by SYSTEM D1 A. Sig=254.4 Ref=off (KGB-II-74.D) mAU 3 700 600 500 400 300 200 18.220 3609 100 0 chic 15 DAD1B 5 LL74 D mAU _ 120 100 80 -60 -40 -20 -385 0 Area Percent Report Sorted By : Signal : Multiplier 1.0000 1.0000 Dilution Use Multiplier & Dilution Factor with ISTDs Signal 1: DAD1 A, Sig=254,4 Ref=off Height Peak RetTime Type Width Area Area # [min] [min] [mAU*s] [mAU] % 1 2.357 BB 0.0506 9.57488 2.89289 0.1960 2 2.587 VV 0.0674 5.21559 3 2.672 VB 0.0747 5.29344 1.13854 0.1067 1.05193 0.1083 3.13893 0.2111 4 2.989 BB 0.0503 10.31255 5 13.609 BB 0.0929 10.03435 1.56261 0.2054 0.0867 4836.85352 845.49213 98.9963 6 16.371 BB 7 18.220 BB 0.0974 8.60644 1.33185 0.1761 Totals : 4885.89077 856.60887 1290 Infinity 3/8/2019 6:05:08 PM SYSTEM

HPLC data of the compound **5***i*

Data File D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\KGB-II-75.D Sample Name: KGB-II-75



HPLC data of the compound **5***j*

5 20.217 BB 0.0996

1.24146 0.8499

8.04234 6 22.270 BB 0.1046 906.08051 134.56239 95.7504 Sample Name: KGB-II-81 _____ Acq. Operator : SYSTEM Seq. Line : 12 Acq. Instrument : 1290 Infinity Location : P1-A-06 Injection Date : 3/8/2019 8:09:26 PM Inj: 1 Inj Volume : 10.000 µl Acq. Method : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\190308_kim.M Last changed : 3/8/2019 3:14:53 PM by SYSTEM Analysis Method : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\190308_kim.M (Sequence Method) Last changed : 3/8/2019 3:30:48 PM by SYSTEM D1 A, Sig=254,4 Ref=off (D:/Data/9171/9171-190308_kim 2019-03-08 14-28-43/KGB-II-81.D - D:/DATA/9171/9171-190308_KIM mAU 3 500 -400 -300 200 -100 -8 0 15 mAU 🛔 60 -50 40 -30 -20 10 -0 _____ _____ Area Percent Report -----Sorted By Multiplier : Signal 1.0000 1.0000 Use Multiplier & Dilution Factor with ISTDs Signal 1: DAD1 A, Sig=254,4 Ref=off Signal has been modified after loading from rawdata file! Peak RetTime Type Width Area Height Area # [min] [mAU*s] [mAU] % 1 12.889 BB 0.0828 15.31868 2.84445 0.4422 2 15.528 BB 0.0833 3449.07275 635.58429 99.5578 Totals : 3464.39143 638.42874

Data File D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\KGB-II-81.D

HPLC data of the compound **5***k*

Data File D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\KGB-II-79.D Sample Name: KGB-II-79

Acq. Operator : SYSTEM Seq. Line : 11 Location : P1-A-05 Acq. Instrument : 1290 Infinity Inj: 1 Injection Date : 3/8/2019 7:38:34 PM Inj Volume : 10.000 µl Sequence File : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\9171-190308_kim.S Method : D:\Data\9171\9171-190308_kim 2019-03-08 14-28-43\190308_kim.M (Sequence Method) Last changed : 3/8/2019 3:14:53 PM by SYSTEM DAD1 A, Sig=254,4 Ref=off (KGB-II-79.D) mAU 1 300 250 200 -150 100 2.381 50 -0 15 10 205 DAD1 B, Sig=365.4 Ref=off (KGB-II-79.D mAU 3 70 60 -50 -40 30 20 2,380 10 0. 15 Area Percent Report Sorted By . Signal Multiplier : 1.0000 : Dilution 1.0000 Use Multiplier & Dilution Factor with ISTDs Signal 1: DAD1 A, Sig=254,4 Ref=off Peak RetTime Type Width Height Area Area [min] [mAU*s] [mAU] % # [min] 1 2.381 BB 0.0486 9.12424 3.07989 0.4171 2 3.019 BB 0.0474 9.00926 2.97110 0.4118 3 17.491 BB 0.0906 2169.41211 368.91376 99.1711 Totals : 2187.54562 374.96475



HXY-4-77-1

exp5 std13c

tpwr 55 pw 10.1 d1 2.000 tof 1043.3 nt 1500 ct 240 alock n gain not used FLAGS 11 n n pp y hs nn DISPLAY sp -1091.8 wp 19238.7 vs 264 sc 0 wc 250 hzmm 76.95 is 41.78 rfl 9786.4 rfp 7788.6 th 12 ins 1.000 ai ph	PROCESSING b 2.00 wtfile proc ft fn not used math f werr wexp wbs wnt .			No B		
			84.671 77.551 77.230 76.299		25.033	





















-0.0052 2.5000 2.4550 2.4376 2.4199 $\begin{array}{c} 1.5693\\ 1.5512\\ 1.5512\\ 1.5151\\ 1.4865\\ 1.4865\\ 1.4865\\ 1.4292\\ 1.4113\\ 0.9412\\ 0.9231\\ 0.9050 \end{array}$ 5.4382 5.4220 5.2036 5.1941 5.1637 5.1637 4.4409 4.4328 4.4178 4.4099 4.3041 4.3041 4.2968 3.8470 3.8240 3.3426 2.9365 - 7.9928 - 7.9909 7.0894 7.0810 6.7671 6.7533 6.7595 6.7595 6.1150 NHMe C₄H₉ но он 5b · T 0.5 ppm 1.5 1.0 3.5 2.5 2.0 5.5 5.0 4.5 4.0 3.0 7.0 6.5 6.0 7.5 9.5 9.0 8.5 8.0 2.0976 3.0810 1.0334 1.0229 2.1530 1.0000 1.0094 2.4924 1.0128 1.1126 0.9383 1.8629 1.0022


































1 155.3815 150.8029 149.6965 148.7606 - 119.3217 -- 117.1567 -- 114.5275 -134.0309- 79.9948 - 76.2115 50.1169 50.0104 49.00104 49.7975 49.4780 49.4780 37.6038 ~ 27.1184 26.7648 19.7995 19.3505 -66.5284 --3.3704 --3.4302 --3.5460 --4.6172 CI TBSÒ ÓTBS 21a X. 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 30 40 20 10 ppm 0


















































4



























E.























